A Study of LY3023414 in Participants With Advanced Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced Cancer|Metastatic Cancer|Non-Hodgkin's Lymphoma|Metastatic Breast Cancer|Malignant Mesothelioma|Non-small Cell Lung Cancer
Interventions: DRUG: LY3023414|DRUG: Midazolam|DRUG: Fulvestrant|DRUG: Pemetrexed|DRUG: Cisplatin|DRUG: Abemaciclib|DRUG: Letrozole
Sponsor: Eli Lilly and Company